0 Comments | Post a commentCategory - Senior Citizen Health and Healthy Living
On May 3rd 2023 FDA Approved First Respiratory Syncytial Virus (RSV) Vaccine Arexvy (Developed by GlaxoSmithKline Biologicals) for Individuals 60 Years of Age and Older for use in the United States.
Respiratory syncytial virus or RSV is a highly contagious virus that causes infections of the lungs and breathing passages in individuals of all age groups. RSV circulation is seasonal, typically starting during the fall and peaking in the winter. In older adults, RSV is a common cause of lower respiratory tract disease (LRTD), which affects the lungs and can cause life-threatening pneumonia and bronchiolitis (swelling of the small airway passages in the lungs). According to the U.S. Centers for Disease Control and Prevention, each year in the U.S., RSV leads to approximately 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults 65 years of age and older.
Among a subset of these clinical trial participants, the most commonly reported side effects by individuals who received Arexvy were injection site pain, fatigue, muscle pain, headache and joint stiffness/pain.
Source - FDA.gov website